Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08VAR
|
|||
| Former ID |
DIB015100
|
|||
| Drug Name |
APH-0812
|
|||
| Synonyms |
Bryostatin-1 + HDAC inhibitor combination (HIV-1 infection), Aphios
Click to Show/Hide
|
|||
| Indication | Human immunodeficiency virus-1 infection [ICD-11: 1C62; ICD-10: B20-B24] | Phase 2 | [1], [2] | |
| Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 42] | Phase 1 | [3] | ||
| Company |
Aphios Corp
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histone deacetylase (HDAC) | Target Info | Inhibitor | [1], [2] |
| Protein kinase C (PRKC) | Target Info | Inhibitor | [1], [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62. | |||
| REF 2 | Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest. 2003;21(6):924-36. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.